Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation

NCT05761470 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

66

Enrollment

OTHER

Sponsor class

Conditions

Her-2 Negative Breast Cancer
HRR Gene Mutation

Interventions

DRUG: Camrelizumab
DRUG: Fluzoparib
DRUG: Nab-paclitaxel

Sponsor

Ying Lin